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Abstract
Background: Current clinical guidelines recommend treating chronic hepatitis B virus (HBV) infection in a minority
of cases, but there are relatively scarce data on evolution or progression of liver inflammation and fibrosis in cases
of chronic HBV (CHB) that do not meet treatment criteria. We aimed to assess the impact of TDF on liver disease,
and the risk of renal impairment in treated CHB patients in comparison to untreated patients.
Methods: We studied a longitudinal ethnically diverse CHB cohort in the UK attending out-patient clinics between
2005 and 2018. We examined TDF treatment (vs. untreated) as the main exposure, with HBV DNA viral load (VL),
ALT, elastography scores and eGFR as the main outcomes, using paired tests and mixed effects model for
longitudinal measurements. Additionally, decline of eGFR during follow-up was quantified within individuals by
thresholds based on clinical guidelines. Baseline was defined as treatment initiation for TDF group and the
beginning of clinical follow-up for untreated group respectively.
Results: We included 206 adults (60 on TDF, 146 untreated), with a median ± IQR follow-up duration of 3.3 ± 2.8
years. The TDF group was significantly older (median age 39 vs. 35 years, p = 0.004) and more likely to be male
(63% vs. 47%, p = 0.04) compared to the untreated group. Baseline difference between TDF and untreated groups
reflected treatment eligibility criteria. As expected, VL and ALT declined significantly over time in TDF-treated
patients. Elastography scores normalised during treatment in the TDF group reflecting regression of inflammation
and/or fibrosis. However, 6/81 (7.4%) of untreated patients had a progression of fibrosis stage from F0-F1 to F2 or
F3. There was no evidence of difference in rates or incidence of renal impairment during follow-up in the TDF vs.
untreated group.
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Conclusions: Risk of liver inflammation and fibrosis may be raised in untreated patients compared to those
receiving TDF, and TDF may benefit a larger percentage of the CHB population.
Keywords: Liver fibrosis, eGFR, Tenofovir Disoproxil fumarate (TDF) therapy, Chronic hepatitis B, Renal impairment
Background
The World Health Organisation (WHO) estimates that
only 10.5% of the 257 million individuals living with
chronic HBV infection are aware of their infection, and
that among these, < 20% are receiving antiviral treatment
[1]. Nearly one million annual deaths are attributable to
HBV, resulting largely from progression to cirrhosis and
hepatocellular carcinoma (HCC). Curing chronic HBV in-
fection (CHB) is challenging due to the persistence of co-
valently closed circular DNA (cccDNA) in infected
hepatocytes [2]. However, treatment with nucleot(s)ide
analogues (NAs) can suppress viral replication, thus redu-
cing the risk of inflammatory liver disease, cirrhosis and
HCC [2, 3]. HBV surface antigen (HBsAg) loss, sometimes
termed ‘functional cure’, is regarded as the optimal end-
point of current treatment in clinical guidelines, but is in-
frequently achieved, as evidenced by the annual rate of
HBsAg loss ranging from 0.12 to 2.7% [4–6]. Therefore,
NA therapy is typically long-term, and can be life-long [2].
Existing CHB guidelines [2, 3, 7] recommend stratify-
ing patients for therapy based on demographic, clinical
and laboratory parameters, such that only a minority
(e.g., ranging from 2% ~ 31% in different settings [8–10])
are treatment-eligible. Tenofovir disoproxil fumarate
(TDF) is an affordable, well-tolerated NA that has a high
genetic barrier to resistance, and is thus the most com-
monly used first-line option for CHB patients. Long-
term efficacy of TDF has been confirmed by extended
follow-up, demonstrating viral suppression [11], im-
provement in liver histology in patients with baseline
cirrhosis [12, 13], and reduced cumulative probability of
HCC, hepatic decompensation, death and liver trans-
plantation, compared to non-treatment [14]. Although
previous studies provide evidence for the beneficial asso-
ciation of TDF treatment with HCC or cirrhosis risk, the
influence of TDF on the evolution or progression of liver
inflammation and fibrosis in non-cirrhotic HBV patients
is less well understood [15].
Benefits of TDF therapy must be balanced with con-
cerns about potential risks, of which the most widely
recognised is renal toxicity [2]. However, the long-term
renal safety of TDF in CHB patients remains controver-
sial [15–20]. Most evidence for TDF-mediated renal in-
jury comes from human immunodeficiency virus (HIV)
cohorts, in which associations may be confounded by
other drugs, comorbidities, or HIV-associated nephropa-
thy [21, 22]. HBV guidelines produced by the European
Association for the Study of the Liver (EASL) recom-
mend that all TDF-treated patients undergo renal moni-
toring [2]. One study carried out among CHB patients
with high HBV DNA viral load (> 6 log10 IU/ml) re-
ported that TDF treatment was associated with a higher
incidence of acute kidney injury (AKI) compared to
ETV, but this difference was only borderline significant
after three years follow-up [16]. Similar findings have
been documented in other cohorts [17]. In patients with
baseline renal impairment and diabetes mellitus, TDF
may increase the risk of renal function decline [23, 24].
However, this observation is not consistent, as other
studies have failed to identify significant difference in
the risk of renal events between TDF- and ETV-treated
patients [15, 18, 19], and have not reported deteriora-
tions in renal function on TDF therapy [20] particularly
if there is no renal impairment at baseline [24].
Heterogenous findings regarding the risk of renal tox-
icity for TDF-treated patients may be due to differences
in the characteristics of patient cohorts in terms of age,
estimated glomerular filtration rate (eGFR) at baseline,
and prevalence of other chronic health conditions such
as hypertension and diabetes [25, 26].
Overall, most previous studies have focused on longi-
tudinal comparison of CHB patients treated with TDF
vs. non-TDF agents [11–20, 24, 27], but studies compar-
ing changes of liver and/or renal function over time in
TDF treated vs. untreated populations are limited [23,
28, 29]. Furthermore, previous studies have typically only
compared average efficacy or renal safety of TDF at a
population level at each time point, rather than examin-
ing longitudinal changes in liver or renal function at the
individual patient level. The latter can avoid ecological
fallacy and provide more meaningful insights to help
identify untreated CHB cases who might benefit from
treatment.
To examine the influence of TDF on risk of inflamma-
tory liver disease, and to assess the renal safety of TDF
in CHB patients, we analysed longitudinal changes in
liver enzymes, elastography scores, and renal function
both at a population- and individual-level, comparing
TDF-treated patients to treatment-naïve patients. Specif-
ically, we investigated: a) the effects of TDF treatment
on maintenance of viral suppression, and reversal of liver
inflammation and fibrosis, and b) the risks of renal tox-
icity associated with TDF treatment in CHB patients
with mild/moderate liver disease at baseline.
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Methods
Study cohort
We conducted a longitudinal retrospective study on
an adult CHB cohort in the United Kingdom between
06/2005 and 10/2018. Data were collected from
Oxford University Hospitals (OUH) National Health
Service (NHS) Foundation Trust, a large teaching
hospital trust in the South East of the UK, using a
clinical informatics pipeline supported by the National
Institute for Health Research Health Informatics
Collaborative (NIHR HIC) [6, 30].
We examined TDF treatment (vs. untreated) as the
main exposure, with HBV DNA viral load (VL), ALT,
elastography score and eGFR as the main outcomes.
Baseline is defined as the start date of treatment for
TDF group and the beginning of clinical follow-up for
the untreated group. We planned to censor patients if
they were lost to follow-up, died, or met exclusion cri-
teria during follow-up, whichever occurred first. In prac-
tice, the only event in this category was loss to follow-
up. The inclusion criteria were: (1) patients with CHB
(defined as two positive HBsAg tests and/or detectable
HBV DNA tests at least 6 months apart); and (2) pa-
tients on TDF monotherapy or treatment naïve patients
(i.e., individuals who were not on treatment with NAs or
interferon).
The exclusion criteria were: (1) patients with hepatitis
C virus (HCV), hepatitis delta virus (HDV) or HIV coin-
fection; (2) patients with decompensated cirrhosis at
baseline; (3) patients who had HCC at baseline; (4) pa-
tients who were younger than 18 years at baseline; (5)
patients who had been followed-up for less than 1 year
from baseline; or (6) patients with < 2 measurements of
eGFR.
Laboratory markers
Quantitative HBV DNA testing was undertaken at OUH
NHS Foundation Trust clinical diagnostic microbiology
laboratory using the Cobas TaqMan assay (Roche Diag-
nostics, Branchburg, NJ), with a lower limit of detection
of 9 IU/ml. Serum HBV e-antigen (HBeAg) was mea-
sured using Centaur (09/2004–12/2014) or Abbott
Architect i2000SR (Abbott Laboratories, Chicago, IL)
(12/2014–10/2018). Quantitative HBsAg was tested
using Centaur (09/2004–12/2014) or Abbott Architect
i2000SR (Abbott Laboratories, Chicago, IL) (12/2014–
10/2018) with a lower limit of detection of 0.05 IU/ml.
Alanine transaminase (ALT) was tested using Siemens
ADVIA 2400 (02/2013–01/2015) or Abbott Architect
c16000 or c8000 (Abbott Laboratories, Chicago, IL) (01/
2015–10/2018) with the normal reference range from 10
to 45 IU/L. Our clinical diagnostic laboratory does not
set different ALT reference ranges for males and
females. Creatinine was measured in micromoles per
litre (μmol/l) in this study with a normal reference range
of 64 to 104 μmol/l.
We defined: (a) virologic response as detectable serum
HBV DNA VL at baseline which is suppressed to < 20
IU/ml during the follow-up, and after which there is no
increase of ≥ 1 log10 IU/ml from the nadir level achieved
[2]; (b) HBeAg loss as a change from being HBeAg posi-
tive to HBeAg negative; (c) HBeAg seroconversion as
the new detection of antibody to HBeAg (anti-HBe); (d)
HBsAg loss as negative HBsAg or undetectable HBsAg
by quantitative test following a previously positive result;
(e) biochemical responses as the normalisation of ALT
levels (i.e., decline of baseline ALT levels to ≤ 45 IU/L
and maintaining this level during the follow-up period).
Liver fibrosis assessment
We evaluated transient elastography (TE) (or FibroScan),
a non-invasive test measuring liver stiffness in kiloPas-
cals (kPa), as a marker of liver inflammation and/or fi-
brosis [31]. No universally-agreed thresholds are
available to map TE values to histological METAVIR
stages [32], but TE is well-validated in both HCV and
HBV and cut-off values have been suggested in these
populations [33, 34]. We used the following thresholds
for fibrosis stages: F0 with TE score of < 7.0 kPa, F1 with
TE score of ≥ 7.0 kPa to < 8.0 kPa, F2 with TE score of
≥ 8.0 kPa to < 10.0 kPa, F3 with TE score of ≥ 10.0 kPa
to < 14.0 kPa, and F4 with TE score of ≥ 14 kPa [34].
Renal function assessment
eGFR is used to measure renal function, which was dir-
ectly reported by our clinical laboratory with a unit of
ml/min/1.73m2. During the study period, the Modifica-
tion of Diet in Renal Disease (MDRD) Study equation
was used by our laboratory for eGFR calculation. eGFR
is typically classified into five categories, G1-G5, used to
monitor the development or progression of chronic
kidney disease (CKD) [35], as follows:
 Normal kidney function defined as eGFR ≥ 90 ml/
min/1.73m2 (G1);
 Mildly decreased kidney function if eGFR 60–89 ml/
min/1.73m2 (G2);
 Mild-moderate loss of kidney function if eGFR 45–
59 ml/min/1.73m2 (G3a);
 Moderate-severe loss of kidney function if eGFR 30–
44 ml/min/1.73m2 (G3b);
 Severe loss of kidney function if eGFR 15–29 ml/
min/1.73m2 (G4);
 Kidney failure if eGFR < 15 ml/min/1.73m2 (G5).
Adverse events related to AKI are defined as an eleva-
tion in serum creatinine of ≥ 0.3 mg/dl (26.5 μmol/l in
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this study) or ≥ to 1.5 times from a known or presumed
baseline based on AKI clinical guidelines [36–38].
Ethnicity data
Ethnicity was self-reported according to NHS standard
ethnic category code list [39], and we used the following
top-level categories: “Asian”, “Black”, “Mixed”, “White",
or “Other”; ethnic groups.
Data extraction
As data used in this study were collected via a pipeline
supported by NIHR HIC and stored in a central database
[30], we used structured query language (SQL) tech-
niques for data retrieval and extraction. We focused on
longitudinal changes in biomarkers, and therefore for
each patient we collected data at baseline and at multiple
subsequent follow-up time points at 3, 6, 12, 18, 24, 30,
36, 42 and 48 months. As this is routinely collected clin-
ical data, the time intervals of follow-up were not regular
with missing data at certain time points. To fully use the
irregular data for longitudinal change pattern analysis,
we used an imputation scheme, i.e., if the data at a cer-
tain time point t was missing, we used the data closest
to that time point within t ± 1.5 or 3months (Fig. S1).
Statistical analysis
We conducted all statistical analyses in R (version: 3.6.1).
Significance tests were two-sided and p values < 0.05 were
deemed statistically significant. We used Fisher’s exact test
for categorical variables, while for continuous variables we
performed Wilcoxon rank sum test. Log transformation
was used for HBV DNA VL, and ALT values were trans-
formed into fold of the upper limit of normal (ULN). To
examine the efficacy of TDF on VL suppression (or ALT
normalisation), we compared the VL (or ALT level) at dif-
ferent time points after treatment to VL (or ALT level) at
baseline by using paired t-test or paired Wilcoxon test as
appropriate, depending on the size of samples or the result
of normality test by Shapiro-Wilk’s test. We applied the
Kaplan-Meier (K-M) method to estimate the rates of viro-
logic response over time. We used log rank tests to com-
pare the difference in the cumulative rates of HBV DNA
VL suppression or ALT normalisation between subgroups.
As censoring could influence interpretation of K-M curves,
we marked censored subjects on the curve by points. If the
event of interest (i.e., HBV DNA VL suppression, ALT nor-
malisation) did not occur before the end of follow-up, this
patient was censored (the total time to an event for this
subject could not be accurately determined) [40].
To further evaluate and compare the changes of HBV
DNA VL, ALT, TE, and eGFR over time between TDF
and untreated groups, we used linear mixed effects
models for repeated measures [41, 42] using the lme4
package (version: 1.1-23) [43]. Linearity assumption was
checked by residual plot. If the linearity assumption was
not met, we applied a nonlinear transformation [42]. In
the crude (unadjusted) models, we considered follow-up
time, group, and group-by-time interaction as fixed ef-
fects and incorporated random intercepts for individuals.
We used the likelihood ratio test to evaluate whether it
is necessary to add a random slope for time to a model
[41]. We then adjusted for baseline age, gender, and eth-
nicity in these models. We also performed sensitivity
analysis to include further adjustment for other imbal-
anced baseline characteristics if these data were
available.
We stratified TE scores into different categories for
matching METAVIR stages at each time point. To
examine the progression of liver fibrosis, we analysed
the changes of TE score categories for individuals from
baseline to the end of follow-up. To quantify the longi-
tudinal variability of eGFR within individuals, we used
the standard deviation (SD) of eGFR during the follow-
up period for each patient, which measures the ampli-
tudes of eGFR values from mean eGFR level within an
individual. Furthermore, to examine changes in renal
function, we stratified the total decline of eGFR levels
during the follow-up within individuals into three cat-
egories relative to baseline or the first available observa-
tion, i.e., decline greater than 10ml/min/1.73m2, decline
less then 10 ml/min/1.73m2 and no decline, based on
the definition published by NICE guidelines [35]. To
examine the progression of CKD, we analysed the drop
of eGFR categories (G1, G2, G3a, G3b, G4, G5 as de-
fined). To assess probable AKI events, we stratified the
maximum change amplitude of serum creatinine levels
during the follow-up into three different elevation levels
based on AKI clinical guidelines [36–38], i.e., (a) eleva-
tion ≥ 26.5 μmol/l or ≥ 1.5 times, (b) elevation <
26.5 μmol/l and < 1.5 times, and (c) no elevation. The
maximum change amplitude here is defined as the max-
imal value of changes in serum creatinine levels between
every two consecutive tests within a patient.
Results
The detailed information for selecting patients based on
each criterion is illustrated in a flow diagram (Fig. S2). We
included 206 patients (60 patients treated with TDF
monotherapy, and 146 patients without treatment). All pa-
tients had at least two measurements of ALT, eGFR, and
serum creatinine. 202/206 patients had at least two mea-
surements of HBV DNA VL.
Patients treated with TDF are older with more prevalent
liver fibrosis compared to the untreated group at
baseline
We compared baseline characteristics for individuals
treated with TDF vs. non-treated (Table 1). There was
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no significant difference in the length of follow-up be-
tween the two groups (p = 0.2). Treated patients were
significantly older than those untreated (median 39 vs.
35 years, respectively, p = 0.004), with more males (63%
vs. 47%, p = 0.04). As expected, based on stratification
for treatment using national guidelines [7], patients
treated with TDF were more likely to have raised ALT
(p < 0.001), higher HBV DNA VL (p < 0.001), and higher
TE scores (p = 0.002) at baseline. However, there was no
difference in baseline renal function, based either on
eGFR, or creatinine.
Interestingly, a higher TDF treatment rate was ob-
served in Asian patients compared to patients from
other ethnic groups (55.0% vs. 22.6%, p < 0.001). How-
ever, ethnicity was unreported in 47 (22.8%) patients
(Table 1). With analysis stratified by ethnicity (Table
S1), we found a significantly higher proportion of pa-
tients aged > 60 years, significantly higher ALT levels
(p = 0.01), and higher HBV DNA VL (p = 0.02) at base-
line in Asian patients, compared to patients of other eth-
nicities. These findings may also be in keeping with a
higher HBeAg-positive prevalence amongst Asian pa-
tients but HBeAg status was missing in 14.3–40.9% of
cases (Table S1), limiting our ability to make meaningful
comparisons.
The majority of patients on TDF treatment suppressed VL
within 12months, while untreated individuals maintained
a virological set point during follow-up
In the TDF group, a significant decline was observed in
a pairwise comparison of VL at baseline compared to all
later time points (all p < 0.0001, Fig. 1A, left hand panel).
In the untreated group, a significant difference was only
found in the pairwise comparison of VL at selected later
time points compared to baseline VL and there was no
significant difference between VL at baseline and 12
months, or between baseline and the final timepoint of
48 months (Fig. 1A, right hand panel). The crude mixed
effects model further revealed that changes in VL over
time were significantly different between the TDF-
treated and untreated groups (p < 0.001, Table 2) with a
faster decline over time in the TDF-treated group, as ex-
pected. Similar longitudinal trends of VL were obtained
from the model adjusted for demographics (Table 2) and
sensitivity analysis with further adjustment for baseline
ALT and TE scores (Table S2).
In the TDF group, 81.3% of patients suppressed VL to
< 20 IU/ml at 1 year, 88.1% at 2 years, and 94.1% at 3
years, while all had VL < 2 log10 IU/ml at the end of
follow-up (Fig. 1B). In contrast, only ~ 25% of untreated
patients had VL < 20 IU/ml at one to 3 years, with me-
dians (±IQR) of 2.8 ± 1.5 log10 IU/ml, 2.6 ± 1.6 log10 IU/
ml, and 3.0 ± 1.6 log10 IU/ml at 1 year, 2 years, and 3
years, respectively. At the end of follow-up only 36% of
the untreated group had VL < 2 log10 IU/ml (Fig. 1B).
Kaplan-Meier analysis further estimated that the me-
dian time to virologic suppression was 6months for the
TDF group (Fig. 1C). 51/60 (85%) patients in the TDF
group vs. 126/146 (86.3%) patients in the untreated
group had baseline VL data (p = 0.8), and all these pa-
tients had VL > 20 IU/ml at baseline. Among these pa-
tients, 94.1% (48/51) in the TDF group vs. 34.9% (44/
126) in the untreated group had suppressed VL to < 20
IU/ml during follow-up (p < 0.001). The remaining 3 (3/
51, 5.9%) TDF-treated patients with VL > 20 IU/ml were
censored at 17, 31, and 36months. The remaining 81
(81/126, 65.1%) untreated patients with detectable VL
were censored at a mean of 3.7 years, and none of them
started treatment during follow-up.
An increase of VL by > 1 log10 IU/ml during
follow-up was observed in 2/60 (3.3%) in the TDF
group vs. 25/146 (17.1%) in the untreated group (p =
0.006) (Fig. S3 and Fig. S4). In the untreated group,
there is evidence of a set-point HBV DNA VL, where
17.3% of variations in VL were accounted for by
within-patient variation, compared to 82.7% between
patients, as previously described [44].
Patients treated with TDF have higher baseline ALT levels
that normalise with treatment
In the TDF group, ALT levels progressively normalised
after treatment initiation, and significant differences
were observed at six months and at later timepoints with
a pairwise comparison to baseline ALT levels (all p <
0.01, Fig. 2A). In the untreated group, no differences
were found for ALT at any later timepoints compared to
baseline levels (Fig. 2A). Furthermore, mixed effects
models showed that changes of ALT over time were sig-
nificantly different for TDF-treated and untreated groups
(p < 0.001, Table 3) with a faster decrease over time in
TDF-treated group; consistent findings were obtained
from sensitivity analysis (Table S3). In the treated group,
> 70% of patients had ALT levels within the normal
range at 12 months and later timepoints, while ~ 85% in
untreated group had normal ALT level at each time
point (Fig. 2B).
Although the proportion of patients who had abnor-
mal ALT levels at baseline was significantly higher in the
TDF group (30/60, 50.0%) compared to the untreated
group (22/146, 15.1%) (p < 0.0001), ALT normalisation
was observed in both these groups during follow-up, i.e.,
93.3% (28/30) in treated patients and 86.4% (19/22) in
untreated patients (p = 1). The remaining two (2/30,
6.7%) TDF-treated patients with abnormal ALT were
censored at 35 and 56months as time to ALT normal-
isation could not be evaluated. The remaining three (3/
22, 13.6%) untreated patients with abnormal ALT were
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Table 1 Baseline characteristics of adults with chronic hepatitis B virus infection (Tenofovir disoproxil fumarate vs. untreated)
TDF group Untreated group p-value
(n = 60) (n = 146)
Follow-up duration (years) 3.8 [2.6, 4.6] 3.0 [1.9, 4.9] 0.176
Age (years) 39 [33, 48] 35 [30, 40] 0.004
Age > 60 (years) (%) 4 (6.7) 5 (3.4) 0.510
Gender (%)
Female 20 (33.3) 71 (48.6) 0.064
Male 38 (63.3) 68 (46.6) 0.042
Unreported 2 (3.3) 7 (4.8) 1
Ethnicity (%) §
Asian 33 (55.0) 33 (22.6) < 0.001
Black 11 (18.3) 31 (21.2) 0.780
White 9 (15.0) 28 (19.2) 0.610
Other 4 (6.7) 10 (6.8) 1
Unreported 3 (5.0) 44 (30.1) < 0.001
HBeAg positive (%) 5 (8.3) 4 (2.7) 0.126
Diabetes (%) †
Yes 2 (3.3) 6 (4.1) 1
No 25 (41.7) 72 (49.3) 0.398
Unknown 33 (55.0) 68 (46.6) 0.344
ALT (x ULN) (IU/L) 1.1 [0.7, 1.8] 0.6 [0.4, 0.8] < 0.001
HBV DNA (log10 IU/ml) 4.8 [4.1, 6.1] 2.7 [1.9, 3.5] < 0.001
qHBsAg (log10 IU/ml) 3.0 [3.0, 3.6] 3.0 [3.0, 3.6] 0.425
Liver stiffness (kPa) ‡ 7.5 [5.0, 10.0] 5.0 [4.0, 6.0] 0.002
< 8 kPa 11 (18.3) 69 (47.3) < 0.001
≥ 8 kPa and < 14 kPa 9 (15.0) 6 (4.1) 0.015
≥ 14 kPa 2 (3.3) 0 (0.0) < 0.001
Unavailable 38 (63.3) 71 (48.6) 0.077
eGFR (ml/min/1.73m2) # 90 [89, > 90] 90 [87, > 90] 0.613
≥ 90ml/min/1.73m2 29 (48.3) 72 (49.3) 1
60 ~ 89ml/min/1.73m2 11 (18.3) 30 (20.5) 0.865
< 60 ml/min/1.73m2 0 (0) 1 (0.97) 1
Unavailable 20 (33.3) 43 (29.5) 0.702
Serum creatinine (μmol/l) 72 [57, 80] 73 [57, 83] 0.766
Serum urea (mmol/l) 5 [4, 6] 4 [4, 6] 0.199
Albumin (g/L) 42 [38, 44] 41 [38, 45] 0.861
ALP (IU/L) 114 [63, 163] 96 [63, 150] 0.266
Bilirubin (total) (umol/L) 10 [8, 15] 9 [7, 12] 0.104
Platelet count (× 109/L) 205 [162.5, 240.0] 219 [185.5, 252.2] 0.078
Data are the median [interquartile range] or number (%) unless otherwise indicated. For categorical variables, Fisher's exact test was performed for comparison on
cells with small counts (< 5), otherwise Chi-square test was used. For continuous variables, Wilcoxon test was used for comparison due to non-normality. p
values < 0.05 were deemed statistically significant, marked in bold. § Ethnicity was originally self-reported by patients according to NHS standard ethnic categories.
† Diabetes was diagnosed using glycated haemoglobin (HbA1c), an HbA1c of 6.5% or 47.5 mmol/mol is a typical threshold for diagnosing diabetes. ‡ Liver
stiffness was measured by transient elastography score in kiloPascals (kPa). # For eGFR, if a level was greater than 90ml/min/1.73m2, it was not quantified by the
hospital laboratory system. ALT Alanine aminotransferase; eGFR estimated Glomerular Filtration Rate; ALP Alkaline phosphatase; TDF Tenofovir disoproxil fumarate;
qHBsAg quantitative HBsAg level; ULN upper limit of normal
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censored at 12, 56, and 66 months, and none of them
started treatment during follow-up.
TE score regressed in patients treated with TDF and
progressed in untreated patients
Baseline TE scores were available for 22/60 (36.7%)
TDF-treated patients vs. 75/146 (51.4%) untreated pa-
tients. During follow-up, TE scores were available for
52/60 (86.7%) patients in the TDF treated group vs. 121/
146 (82.9%) in the untreated group. Among these, 30/52
(57.7%) treated vs. 81/121 (66.9%) untreated patients
had longitudinal measurements (at least two TE mea-
surements). In the TDF group, TE score was 7.5 ± 5
(median ± IQR) kPa at baseline, and declined to 6.0 ± 1.5
kPa at four years (Fig. 3A, left panel), while in the un-
treated group the TE scores were 5.0 ± 2.0 kPa at base-
line and at most subsequent time points during follow-
up, however elevated TE scores were observed in
Fig. 1 Longitudinal analysis of HBV DNA VL in chronic HBV patients with TDF treatment vs. without treatment. (A) Distribution of HBV DNA VL at
each time point; (B) Stratification of HBV DNA VL at each time point; (C) Kaplan-Meier analysis to estimate the probability of patients with HBV
DNA VL > 20 IU/ml in each group over time. In Kaplan-Meier analysis, real dates were used for calculating the time to HBV DNA VL suppressed < 20
IU/ml, rather than the imputed time points and censored subjects were marked on the curve by dots. * p-value < 0.05, ** p-value < 0.01, *** p-value <
0.001, **** p-value < 0.0001. HBV, hepatitis B virus; TDF, Tenofovir disoproxil fumarate; VL, viral load
Table 2 Changes of HBV DNA VL (log10 IU/ml) over time assessed by linear mixed effects models for patients treated with TDF vs.
untreated
Crude model Adjusted for baseline age, gender, ethnicity
Coefficient β (95% CI) p-value Coefficient β (95% CI) p-value
(Intercept) 2.783 (2.627, 2.939) < 0.001 3.476 (3.020, 3.931) < 0.001
Group 0.162 (− 0.114, 0.437) 0.250 0.123 (− 0.163, 0.409) 0.399
Time −0.013 (− 0.019, − 0.007) < 0.001 −0.013 (− 0.019, − 0.007) < 0.001
Group x Time a −0.041 (− 0.050, − 0.032) < 0.001 − 0.041 (− 0.050, − 0.032) < 0.001
a x indicates the interaction between group and follow-up time. Group = {0,1}, where 0 indicates untreated, 1 indicates TDF. A log transformation was applied to
the dependent variable (HBV DNA) due to nonlinearity. CI confidence interval; TDF Tenofovir disoproxil fumarate; VL viral load
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particular patients (Fig. 3A, right panel). In the TDF
group, elastography stage regressed over time, whilst a
progression to F3 or F4 stages presented at 18, 30, 36,
42 months in the untreated group (Fig. 3B).
The crude mixed effects model revealed that changes
in TE scores over time were significantly different for
TDF-treated and untreated groups (p = 0.006, Table 4),
with a decrease over time in the TDF-treated group (β_
time + 1*β_interaction = − 0.032) but not in the un-
treated group (β_time + 0*β_interaction = 0.006). Similar
longitudinal trends of TE scores were observed based on
the model adjusted for demographics (p = 0.004, Table
4) and sensitivity analysis with further adjustment for
baseline VL and ALT (p = 0.008, Table S4).
There was no evidence of progressive liver fibrosis in
the TDF group (Fig. S5A), whereas in the untreated
group, 90.1% (73/81) of patients were stage F0-F1 at
baseline, of whom 6/81 (7.4%) progressed (four of these
to F2 and two to F3) (Fig. S5B). However, the difference
in progression between the two groups did not reach
statistical significance (0/30 vs. 6/81, p = 0.2). Among
untreated individuals, the baseline TE reading (median ±
IQR) was 6.0 ± 1.0 kPa in the subgroup with progressive
liver fibrosis vs. 5.0 ± 2.0 kPa in the subgroup without
(p = 0.09), and the former subgroup was older (median ±
IQR, 45 (29-47) years vs. 35 (30-42) years, p = 0.5)
(Table S5). These differences were not statistically sig-
nificant, and due to small numbers we were
Fig. 2 Longitudinal analysis of ALT of chronic HBV patients with TDF treatment vs. without treatment. (A) Distribution of ALT levels at each time
point; (B) Stratifications of ALT levels at each time point. * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001, **** p-value < 0.0001. ALT, Alanine
aminotransferase; TDF, Tenofovir disoproxil fumarate
Table 3 Changes of ALT (IU/L) over time assessed by linear mixed effects models for patients treated with TDF vs. untreated
Crude model Adjusted for baseline age, gender, ethnicity
Coefficient β (95% CI) p-value Coefficient β (95% CI) p-value
(Intercept) 30.182 (26.944, 33.421) < 0.001 44.491 (35.438, 53.545) < 0.001
Group 23.566 (17.691, 29.440) < 0.001 21.868 (16.058, 27.677) < 0.001
Time −0.055 (− 0.169, 0.059) 0.346 − 0.055 (− 0.168, 0.059) 0.347
Group x Time a − 0.562 (− 0.752, − 0.372) < 0.001 −0.579 (− 0.768, − 0.390) < 0.001
a x indicates the interaction between group and follow-up time. Group = {0,1}, where 0 indicates untreated, 1 indicates TDF. ALT Alanine aminotransferase;
CI,confidence interval; TDF Tenofovir disoproxil fumarate
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underpowered to detect true associations with confi-
dence (Table S5).
According to EASL or NICE guidelines [2, 7], two
(2/6, 33.3%) of the untreated patients who experi-
enced progression of fibrosis met treatment criteria at
a later time. One met only EASL criteria at 9 months
whilst not meeting NICE criteria - this patient was
followed up to 12 months and did not receive treat-
ment during follow-up. Another patient met both
EASL criteria and NICE treatment criteria at 40
months (due to TE increasing to 12 kPa at this time)
but with no further follow-up data after 40 months.
However, the remaining four (4/6, 66.7%) still did not
meet EASL or NICE criteria for treatment over the
remaining follow-up period.
No statistical difference in HBeAg and HBsAg loss rate
between TDF treated and untreated groups
A small number of patients (n = 9) were HBeAg-positive
at baseline (5 in the TDF group vs. 4 in the untreated
group). HBeAg loss (seroconversion) occurred in 3/5
(60%) in the TDF group and 4/4 (100%) patients in the
untreated group (one untreated patient also had HBsAg
loss). HBsAg loss was recorded in 0/60 patients in the
TDF group vs. 7/146 (5%) patients in the untreated
group. Neither of these differences reached statistical
Fig. 3 Longitudinal analysis of liver stiffness (transient elastography scores) of chronic HBV patients with TDF treatment vs. without treatment. A
Distribution of transient elastography scores at each time point; (B) Stratifications of transient elastography scores at each time point. * p-value <
0.05, ** p-value < 0.01, *** p-value < 0.001, **** p-value < 0.0001. TDF, Tenofovir disoproxil fumarate
Table 4 Changes of TE scores (kPa) over time assessed by linear mixed effects models for patients treated with TDF vs. untreated
Crude model Adjusted for baseline age, gender, ethnicity
Coefficient β (95% CI) p-value Coefficient β (95% CI) p-value
(Intercept) 5.088 (4.693, 5.483) < 0.001 4.586 (3.385, 5.787) < 0.001
Group 1.758 (0.977, 2.540) < 0.001 1.729 (0.926, 2.533) < 0.001
Time 0.006 (− 0.008, 0.020) 0.416 0.006 (− 0.008, 0.020) 0.421
Group x Time a −0.038 (− 0.065, − 0.011) 0.006 −0.040 (− 0.067, − 0.013) 0.004
a x indicates the interaction between group and follow-up time. Group = {0,1}, where 0 indicates untreated, 1 indicates TDF. CI confidence interval; TDF Tenofovir
disoproxil fumarate
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significance (p = 0.4 for HBeAg loss and p = 0.2 for
HBsAg loss).
No significant difference in mild/moderate renal
impairment over time between two groups and similar
risks of CKD progression over time
At baseline, 11/40 treated vs. 31/103 untreated patients
had eGFR < 90.0 ml/min/1.73m2 (27.5% vs. 30.1%, p =
0.8), and 0/40 treated vs. 1/103 untreated patients had
eGFR < 60ml/min/1.73m2 (0 vs. 1%, p = 1) (Table 1).
During follow-up, mild renal impairment (nadir eGFR
60–89ml/min/1.73m2) was present in 60% (36/60) in
TDF group vs. 49% (71/146) in the untreated group (p =
0.2), and moderate renal impairment (nadir eGFR 30–
59ml/min/1.73m2) in 5% (3/60) in TDF group vs. 3% (4/
146) in untreated group (p = 0.4) (Fig. 4A, B).
Using mixed effects regression analysis, the changes of
eGFR over time were not significantly different between
the TDF-treated and untreated groups based on both
the crude model (p = 0.278) and the model adjusted for
demographics (p = 0.268, Table 5). This was consistent
in sensitivity analysis with further adjustment for base-
line VL, ALT, and TE scores (p = 0.659, Table S6).
Variation in eGFR within individuals over time was
not significantly different between the groups (p = 0.2)
(Fig. 4C). We observed a decrease in eGFR of ≥ 10ml/
min/1.73m2 in 8% (5/60) of patients in TDF group and
7% (10/146) of patients in untreated group (p = 0.7, red
sections in Fig. 4D), a decrease in eGFR of < 10ml/min/
1.73m2 in 30% (18/60) in TDF group vs. 18% (26/146) in
untreated group (p = 0.08, blue sections in Fig. 4D).
There was no significant difference in the proportion of
patients with progression of CKD stages between the
TDF group and untreated group (28.3% (17/60) vs.
17.8% (26/146), p = 0.13) (Fig. S6A, S6B).
Risks of AKI events are not associated with TDF treatment
There was no significant difference in variation of serum
creatinine within individuals over time between the
groups (p = 0.8) (Fig. 5A). AKI events arose in 2/60
(3.3%) of TDF-treated patients and 5/146 (3.4%) un-
treated patients (p = 1, Fig. 5B). We also observed a mild
elevation of serum creatinine of < 26.5 μmol/l and < 1.5
Fig. 4 Longitudinal analysis of eGFR of chronic HBV patients with TDF treatment vs. without treatment. (A) Comparison of the proportion of
patients with different categories of nadir eGFR during follow-up between groups; (B) Distribution of CKD stages at each time point; (C) Variation
of eGFR values within individuals over time; (D) Stratifications of eGFR decline levels within individuals over time. In panel A, nadir eGFR is defined
as the lowest levels of eGFR of a patient during follow-up. In panel C, variation in the x-axis is calculated as the standard deviation of eGFR values of
each individual during the follow-up period, y-axis is the probability of patients having a corresponding variation. eGFR, estimated Glomerular Filtration
Rate; CKD, chronic kidney disease; TDF, Tenofovir disoproxil fumarate
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times in 95% (57/60) in TDF group vs. 81% (118/146) in
untreated group (p = 0.009, Fig. 5B). However, the me-
dian (IQR) creatinine in both groups was within the nor-
mal reference range, i.e., 81 (69-93) μmol/l in TDF
group vs. 79 (66-89) μmol/l in untreated group (p = 0.2),
with a small proportion who had creatinine elevated to a
level > ULN (5/57 (8.8%) in TDF group vs. 5/118 (4.2%)
in untreated group, p = 0.3); all of these ten patients had
eGFR < 90 ml/min/1.73m2.
Discussion
Principal findings
In this longitudinal cohort study, using an electronic
pipeline developed by NIHR HIC, we show that CHB
patients treated with TDF therapy suppress HBV vir-
aemia as expected, and this is associated with an im-
provement in liver stiffness when assessed up to ~ 5
years. Liver disease progressed in 7.4% of patients in the
untreated group over the study period and in none of
the TDF treated patients. Although this difference did
not reach statistical significance, this observation
demonstrates evolving liver disease among a subgroup of
untreated patients, highlighting that broadening treat-
ment criteria could be of benefit in preventing liver dis-
ease in a wider pool of the CHB population. This finding
warrants exploration in larger cohorts followed up over
longer time periods.
Value added to the existing literature and clinical
implications
There is currently minimal evidence assessing the devel-
opment or regression of liver disease and changes in
renal function in CHB patients receiving TDF therapy in
comparison to an untreated group – especially in those
without cirrhosis at baseline [12]. A significantly higher
treatment rate in Asian patients (who had higher ALT
levels and HBV VL at baseline compared to other eth-
nicities) is consistent with findings from previous studies
that genotype C (common in Asia) is more likely to be
HBeAg positive for longer, with higher HBV VL [45–
47]. Therefore Asian patients are more likely to meet
current treatment criteria, though we acknowledge that
Table 5 Changes of eGFR (ml/min/1.73m2) over time assessed by linear mixed effects models for patients treated with TDF vs.
untreated
Crude model Adjusted for baseline age, gender, ethnicity
Coefficient β (95% CI) p-value Coefficient β (95% CI) p-value
(Intercept) 85.813 (84.676, 86.950) < 0.001 93.974 (90.352, 97.595) < 0.001
Group 0.991 (− 1.085, 3.068) 0.349 1.76 (− 0.286, 3.805) 0.092
Time − 0.014 (− 0.050, 0.022) 0.449 −0.016 (− 0.051, 0.019) 0.379
Group x Time a −0.034 (− 0.094, 0.027) 0.278 −0.033 (− 0.092, 0.026) 0.268
a x indicates the interaction between group and follow-up time. Group = {0,1}, where 0 indicates untreated, 1 indicates TDF. CI confidence interval; eGFR estimated
glomerular filtration rate; TDF Tenofovir disoproxil fumarate
Fig. 5 Changes of serum creatinine within individuals over time in chronic HBV patients with TDF treatment vs. without treatment. (A) Variation
of serum creatinine levels within individuals over time; (B) Stratifications of serum creatinine elevation levels within individuals over time. In panel
A, variation in the x-axis is calculated as the standard deviation of creatinine values of an patients during the follow-up period, y-axis is the probability
of patients having a corresponding variation. In panel B, red sections represent the percentage of patients had AKI events, which is defined as an
elevation of serum creatinine of ≥ 26.5 μmol/l or≥ 1.5 times compared to previous time point. AKI, acute kidney injury. TDF, Tenofovir
disoproxil fumarate
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ethnicity was unreported for ~ 23% of patients in our
cohort.
Our research has potential implications for clinical
practice. Firstly, since TDF therapy is associated with
disease regression in those without cirrhosis, treatment
may be of benefit to a greater proportion of this popula-
tion. Follow-up is often irregular, and is subject to clin-
ical practice and patient adherence. Due to the
irregularity of follow-up, fibrosis progression may occur
months to years before detection. Wider treatment at
the initial assessment might be advantageous compared
to treatment initiation only after the progression of fi-
brosis has been observed. In this study, most of the un-
treated patients who experienced progression of liver
fibrosis still did not meet treatment criteria at a later
time according to EASL or NICE guidelines. Therefore,
expanding guidelines to offer treatment to more individ-
uals earlier in the course of infection might be of benefit
in such patients for preventing liver disease progression.
Secondly, concerns about renal toxicity should not
limit access to treatment; we found that untreated CHB
patients also had a risk of CKD progression (consistent
with a previous cohort study [28]), which was not signifi-
cantly different from the risk in treated patients. Previ-
ous studies found that risk factors associated with renal
function decline in CHB patients include old age, hyper-
tension, diabetes, baseline impairment in eGFR, and use
of diuretics [48–51]. Therefore, concerns about nephro-
toxicity may be more pertinent in these subgroups, and
risks should be assessed on a case-by-case basis.
A meta-analysis confirms that TDF and tenofovir ala-
fenamide (TAF) are the most effective agents for viro-
logic suppression for both HBeAg-positive and HBeAg-
negative CHB patients [52], and promising short-term
outcomes of TAF have been reported in several studies
indicating reduced nephrotoxicity [53–55]. However, a
recent study of cost-effectiveness of TAF for treatment
of CHB in Canada reported that TAF is not cost-
effective at its current cost with a price of more than
four times that of TDF, without any advantage in effi-
cacy [56]. Hence, TDF is currently still considered the
treatment of choice. For special groups with baseline
renal dysfunction or comorbidities, however, TAF may
be a safer alternative to TDF [23, 24], but long-term effi-
cacy and safety outcomes of TAF need to be confirmed
[57, 58].
Caveats and limitations
The power of our analysis is constrained by sample size,
especially for identifying associations of uncommon out-
comes (e.g. loss of HBsAg and progression of fibrosis in
untreated patients). Although our population is ethnic-
ally diverse, the number of individuals in each group is
small, and the data provides a snapshot of disease in one
UK centre. We recognise that some missing data limits
our ability to perform comparison analysis, e.g. missing
HBeAg status by ethnic group. It will be useful to ex-
plore the HBeAg-positive rate by ethnic group
when more data become available in the future. We re-
duced missingness at those time points of interest
through data imputation using closest time points within
a short period, and performed sensitivity analysis in a
subset of patients who had no missing data for import-
ant covariates at baseline. It would be desirable to per-
form an assessment of the fractional urinary excretion of
phosphate, albuminuria, and proteinuria to assess tubu-
lopathy in future analyses.
We only considered adult patients and no data for spe-
cial groups including pregnant women, or those with
chronic comorbidities such as hypertension, diabetes, or
co-infection with other blood-borne viruses. Therefore,
we may have underestimated treatment impact or risk at
a population level. Similar studies are needed in settings
where other risk factors are more prevalent, e.g., popula-
tions where HIV is co-endemic. Previous investigation
from South Africa reported that adults with HIV/HBV
coinfection on antiretroviral therapy have less chronic
liver disease than those with HBV monoinfection, sug-
gesting an advantage conferred by treatment in the coin-
fected group [59]. We only compared patients on TDF
treatment to untreated; due to infrequent use of ETV,
we have not considered the small subgroup of our popu-
lation treated with this agent. Based on the available
data, we were not able to make a formal assessment of
metabolic bone disease in patients on TDF therapy, nor
could we consider other reported side-effects such as
gastrointestinal disturbance. For expanding treatment
eligibility, assessment of cost effectiveness would be also
necessary in future studies, and the treatment duration
or the necessity of life-long intake of TDF would need to
be further evaluated.
Conclusions
In summary, we show clear benefits of TDF therapy in
an ethnically diverse CHB population, even among pa-
tients with only mild/moderate liver disease at baseline.
These benefits may be relevant to a wider pool of the
untreated CHB population without imposing clinically
significant renal impairment in the time frames observed
here. Studies of larger populations, and over longer pe-
riods of follow-up, are urgently needed to provide the
evidence to underpin expanded treatment guidelines.
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